Figure 1.

Differential outcomes after percutaneous coronary intervention (PCI) among patients with and without diabetes treated with everolimus-eluting or paclitaxel-eluting stents. (A) Among patients without diabetes, the rates of major adverse cardiovascular events were significantly lower for those treated with everolimus-eluting stents (EES) compared to paclitaxel-eluting stents (PES). However, patients with DM had similar outcomes regardless of the drug-eluting stent type. (B) Among patients without diabetes, EES were also associated with significantly decreased rates of target lesion revascularization (TLR). In comparison, there was no relationship between stent type and TLR among patients with DM. (Reproduced, with permission, from Stone et al.³⁶)